Partial agonist actions at dopamine D2L receptors are modified by co-transfection of D3 receptors: Potential role of heterodimer formation

Parkinsonism and Related Disorders

Volumn 14, Issue SUPPL.2, 2008, Pages

  Maggio, Roberto ^a   Novi, Francesca ^b   Rossi, Mario ^b   Corsini, Giovanni U ^b   Millan, Mark J ^c  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Dopamine receptor; G protein coupled receptor; Heterodimer; Partial agonist

Indexed keywords

ADENYLATE CYCLASE; ARIPIPRAZOLE; BIFEPRUNOX; CLOZAPINE; CYCLIC AMP; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; FORSKOLIN; G PROTEIN COUPLED RECEPTOR; NORCLOZAPINE; PARTIAL AGONIST; PRECLAMOL; QUINPIROLE; RHODOPSIN; RISPERIDONE; S 33592;

ARTICLE; CELL STRAIN COS7; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DYSTONIA; ENZYME ACTIVITY; EXTRAPYRAMIDAL SYMPTOM; GENETIC TRANSFECTION; HUMAN; MUSCLE HYPERTONIA; NEGATIVE SYNDROME; OLIGOMERIZATION; POSITIVE SYNDROME; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOLOGY; SEQUENCE HOMOLOGY; SIDE EFFECT;

ADENYLATE CYCLASE; ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; FORSKOLIN; MODELS, BIOLOGICAL; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; TRANSFECTION;

EID: 47049092102     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2008.04.018     Document Type: Article

References (49)

1. Maggio R., Novi F., Scarselli M., and Corsini G.U. The impact of G-protein-coupled receptor hetero-oligomerization on function and pharmacology. FEBS J 272 (2005) 2936-2946
2. Maggio R., Innamorati G., and Parenti M. G protein-coupled receptor oligomerization provides the framework for signal discrimination. published online 14 September. J Neurochem 103 (2007) 1741-1752
3. Missale C., Nash S.R., Robinson S.W., Jaber M., and Caron M.G. Dopamine receptors: from structure to function. Physiol Rev 78 (1998) 189-225
4. 1 and adenosine A1 receptors assemble into functionally interacting heteromeric complexes. Proc Natl Acad Sci U S A 97 (2000) 8606-8611
5. 2 receptors. J Biol Chem 277 (2002) 18091-18097
6. Rocheville M., Lange D.C., Kumar U., Patel S.C., Patel R.C., and Patel Y.C. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288 (2000) 154-157
7. 2 receptor co-activation generates a novel phospholipase C-mediated calcium signal. J Biol Chem 279 (2004) 35671-35678
8. 3 receptor action in rat aortic or mesenteric vascular smooth muscles. Hypertension 43 (2004) 673-679
9. 3 dopamine receptor heterodimers exhibit unique functional properties. J Biol Chem 276 (2001) 30308-30314
10. Inoue A., and Nakata Y. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy. Jpn J Pharmacol 86 (2001) 376-380
11. Tamminga C.A., and Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 2 (2002) 141-147
12. 2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res 1003 (2004) 9-17
13. Kasper S., Lerman M.N., McQuade R.D., Saha A., Carson W.H., Ali M., et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 6 (2003) 325-337
14. Pigott T.A., Carson W.H., Anutosh S., Torbeyns A.F., Stock E.G., Ingenito G.G., and for the Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 64 (2003) 1048-1056
15. Grunder G., Carlsson A., and Wong D.F. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 60 (2003) 974-977
16. 2 receptor antagonistic activity. J Pharmacol Exp Ther 274 (1995) 329-336
17. 1A receptors. J Pharmacol Exp Ther 295 (2000) 853-861
18. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20 (1999) 612-627
19. Van Vliet B.J., Mos J., Van der Heijden J.A.M., Feenstra R., Kruse C.G., and Long S.K. DU-127090: a highly potent, atypical dopamine receptor ligand-a putative potent full spectrum antipsychotic with low EPS potential. Eur Neuropsychopharmacol 10 (2000) P.2.034
20. Wolf W. DU-127090 Solvay/H Lundbeck. Curr Opin Investig Drugs 4 (2003) 72-76
21. 3 partial agonist. J Pharmacol Exp Ther 315 (2005) 1278-1287
22. 3 receptors and potential antipsychotic agent: I. Modulation of dopaminergic transmission in comparison to aripiprazole, preclamol and raclopride. Am Soc Neurosci 26 (2000) [Abstract 97/4]
23. Rivet J.M., Brocco M., Dekeyne A., Dubuffet T., Lavielle G., and Millan M.J. S33592; a benzopyranopyrrole partial agonist at dopamine D2/D3 receptors and potential antipsychotic agent: II. Functional profile in comparison to aripiprazole, preclamol and raclopride. Am Soc Neurosci 26 (2000) 272
24. 2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem 87 (2003) 631-641
25. Novi F., Millan M.J., Corsini G.U., and Maggio R. Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D2L receptors are modified by co-transfection of D3 receptors: potential role of heterodimer formation. J Neurochem 102 (2007) 1410-1424
26. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289 (2000) 739-745
27. Fotiadis D., Liang Y., Filipek S., Saperstein D.A., Engel A., and Palczewski K. Atomic-force microscopy: rhodopsin dimers in native disc membranes. Nature 421 (2003) 127-128
28. 2 receptor homodimer. J Biol Chem 278 (2003) 4385-4388
29. Guo W., Shi L., Filizola M., Weinstein H., and Javitch J.A. Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. Proc Natl Acad Sci U S A 102 (2005) 17495-17500
30. 4 receptor BLT1. J Biol Chem 279 (2004) 49664-49670
31. Fotiadis D., Jastrzebska B., Philippsen B., Müller D.J., Palczewski K., and Engel A. Structure of the rhodopsin dimer: a working model for G-protein-coupled receptors. Curr Opin Struct Biol 16 (2006) 1-8
32. Jordan S., Koprivica V., Dunn R., Tottori K., Kikuchi T., and Altar C.A. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 483 (2004) 45-53
33. 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 315 (2005) 265-272
34. Li Z., Ichikawa J., Dai J., and Meltzer H.Y. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 493 (2004) 75-83
35. Li Z., Huang M., Ichikawa J., Dai J., and Meltzer H.Y. N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology 30 (2005) 1986-1995
36. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28 (2003) 1400-1411
37. 2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol 534 (2006) 63-70
38. Surmeier D.J., Song W.J., and Yan Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci 16 (1996) 6579-6591
39. 3 receptor antagonists as therapeutic agents. Drug Discov Today 10 (2005) 917-925
40. Sokoloff P., Diaz J., Le Foll B., Guillin O., Leriche L., Bezard E., et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 5 (2006) 25-43
41. 3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur J Neurosci 10 (1998) 2565-2573
42. 3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neuroscience 98 (2000) 263-273
43. 3 receptors as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther 90 (2001) 231-259
44. 3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci U S A 9 (1997) 3363-3367
45. 3H]PD 128907. Psychopharmacology (Berl) 128 (1996) 240-247
46. Meador-Woodruff J.H., Damask S.P., Wang J., Haroutunian V., Davis K.L., and Watson S.J. Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 15 (1996) 17-29
47. 3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res 779 (1998) 58-74
48. 3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Brain Res Mol Brain Res 45 (1997) 335-339
49. Heidbreder C.A., Gardner E.L., Xi Z.X., Thanos P.K., Mugnaini M., Hagan J.J., et al. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Rev 49 (2005) 77-105